Bayer is investing more than $685 million in a partnership with Arvinas, aimed at developing the biotech firm's protein degradation technology Proteolysis-Targeting Chimera (PROTAC), for use in human and agricultural products. The companies will also work together to develop new agricultural products; they plan to use PROTAC to eliminate a protein linked to a disease by tagging it with engineered molecules.
Bayer is investing $115m in a partnership with Arvinas, aimed at developing the biotech firm's protein degradation technology Proteolysis-Targeting Chimera (PROTAC), for use in human and agricultural products. The companies will also work together to develop new agricultural products; they plan to use PROTAC to eliminate a protein linked to a disease by tagging it with engineered molecules.